A 32-year-old man with chronic hepatitis B infection (HBeAg-positive, HBV DNA >10^5 copies/mL) and compensated cirrhosis presents for antiviral therapy initiation. Which of the following is the preferred first-line nucleos(t)ide reverse transcriptase inhibitor for this patient?

See the options, answer & explanation

Sign in free to reveal the answer choices, the correct answer, the detailed explanation, and AI-powered insights for this question.